Astrazeneca (AZN) Net Equity Issued and Repurchased (2009 - 2026)

Astrazeneca's Net Equity Issued and Repurchased history runs 17 years deep, the most recent figure standing at $10.0 million for Q1 2026.

• In Q1 2026, Net Equity Issued and Repurchased rose 25.0% year-over-year to $10.0 million; the TTM figure through Mar 2026 stood at $42.0 million (up 5.0% YoY), while the FY2025 annual figure was $40.0 million, up 5.26% from the prior year.
• Net Equity Issued and Repurchased for Q1 2026 stood at $10.0 million, down from $23.0 million in the prior quarter.
• The five-year high for Net Equity Issued and Repurchased was $23.0 million in Q4 2024, with the low at $3.0 million in Q2 2022.
• The 5-year median for Net Equity Issued and Repurchased is $5.0 million (2022), against an average of $8.0 million.
• The sharpest annual moves came in 2023 and 2024: Net Equity Issued and Repurchased dropped 20.0% in 2023, then soared 50.0% in 2024.
• Astrazeneca's Net Equity Issued and Repurchased stood at $3.0 million in 2022, then jumped by 33.33% to $4.0 million in 2023, then soared by 475.0% to $23.0 million in 2024, then changed by 0.0% to $23.0 million in 2025, then plunged by 56.52% to $10.0 million in 2026.
• Business Quant data shows AZN's Net Equity Issued and Repurchased at $10.0 million in Q1 2026, $23.0 million in Q4 2025, and $5.0 million in Q3 2025.